— Research note —
Tirzepatide
Dual GIP and GLP-1 receptor co-agonist investigated for glycemic regulation and body-weight reduction in advanced clinical trials.
Tirzepatide is a 39-residue synthetic peptide engineered by Eli Lilly as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Structurally, the molecule is based on the native GIP sequence with multiple amino-acid substitutions and a C20 fatty diacid moiety conjugated via a linker to lysine at position 20, enabling albumin binding and prolonging the elimination half-life to approximately five days, which supports once-weekly subcutaneous administration in clinical research protocols.
The compound has been characterized as the first member of a new pharmacological class of unimolecular multi-receptor agonists. Preclinical investigations in rodent models of diet-induced obesity and genetic diabetes demonstrated superior reductions in body weight and improvements in glycemic indices compared with selective GLP-1 receptor agonists. These observations motivated an extensive late-stage clinical program, including the SURPASS series in type 2 diabetes and the SURMOUNT series in obesity research.
Across published trials, researchers have reported dose-dependent reductions in glycated hemoglobin and body weight that exceeded those observed with semaglutide head-to-head comparators. Investigators have also examined cardiometabolic endpoints including hepatic steatosis quantified by magnetic resonance imaging-proton density fat fraction, blood pressure, and lipid fractions, with consistent improvements observed across cohorts. Ongoing research programs are extending the molecule into heart failure with preserved ejection fraction, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis.
Tirzepatide remains a focus of academic interest because it provides a tractable pharmacological probe for dissecting the relative contribution of GIP and GLP-1 signaling to appetite, energy expenditure, and insulin secretion. Mechanistic studies in receptor-knockout rodents and human enteroendocrine cell lines continue to refine the model of how balanced agonism at the two incretin receptors yields synergistic rather than additive effects in metabolic research models. The compound is supplied here strictly for laboratory research use and is not intended for human consumption.
Mechanism
Tirzepatide engages both the GIP receptor and the GLP-1 receptor, two class B G-protein coupled receptors expressed on pancreatic beta cells, central nervous system nuclei, and adipose tissue. At the GLP-1 receptor, the peptide functions as a balanced agonist, recruiting Gas and beta-arrestin in proportions that resemble the native ligand. At the GIP receptor, biased signaling has been observed, with relatively preserved cAMP accumulation but attenuated receptor internalization compared with native GIP, a profile thought to limit tachyphylaxis.
Activation of these receptors elevates intracellular cyclic AMP, potentiates glucose-stimulated insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells under hyperglycemic conditions, and slows gastric emptying. Within hypothalamic arcuate and dorsomedial nuclei, receptor engagement modulates POMC and AgRP neuronal activity, producing observed reductions in caloric intake in preclinical feeding studies. Additional effects on brown adipose thermogenesis and white adipose lipolysis have been reported in murine models.
Research history
The molecule, originally designated LY3298176, emerged from a medicinal chemistry program at Eli Lilly aimed at exploiting the underappreciated role of GIP signaling in metabolic regulation. Initial proof-of-concept disclosures appeared in 2018, with phase 1 pharmacokinetic and pharmacodynamic data demonstrating tolerability of once-weekly dosing and dose-dependent reductions in fasting glucose.
The SURPASS phase 3 program, comprising SURPASS-1 through SURPASS-5, enrolled patients with type 2 diabetes across monotherapy, add-on, and active-comparator designs. SURPASS-2, published in the New England Journal of Medicine in 2021, reported superior glycemic control versus semaglutide 1 mg. The SURMOUNT obesity program followed, with SURMOUNT-1 (2022) demonstrating mean weight reductions exceeding 20 percent at the highest dose over 72 weeks in participants without diabetes.
Subsequent investigations have extended into obstructive sleep apnea (SURMOUNT-OSA, 2024), heart failure with preserved ejection fraction (SUMMIT, 2024-2025), and metabolic dysfunction-associated steatohepatitis (SYNERGY-NASH, 2024). Mechanistic work continues in academic laboratories examining biased agonism at GIP, central nervous system penetrance, and the contribution of glucagon-receptor-naive design to the safety margin. The compound has become a reference molecule for the broader class of multi-receptor incretin co-agonists now in development.
References
- Frias JP, et al. 2021. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. PMID: 34170647
- Jastreboff AM, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. PMID: 35658024
- Coskun T, et al. 2018. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. PMID: 30473097
- Rosenstock J, et al. 2021. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. PMID: 34186022
- Willard FS, et al. 2020. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. PMID: 32730231
- Malhotra A, et al. 2024. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. PMID: 38912654
- Loomba R, et al. 2024. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. PMID: 38856224
Do you have any questions about Tirzepatide?
Pick a path. The research assistant has the full literature context loaded.
Information presented in third-person scientific context. Research use only. Not medical advice; not for human consumption.